Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | FASN | P49327 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 7/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19019742 | 1.00 | TSHR (0.55) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL9696124 | 1.00 | TSHR (0.55) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL9696451 | 1.00 | TSHR (0.55) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL19019745 | 1.00 | TSHR (0.55) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL19019743 | 1.00 | TSHR (0.55) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL9357983 | 1.00 | TSHR (0.55) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL9697099 | 1.00 | TSHR (0.55) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL3122524 | 1.00 | TSHR (0.55) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL9696159 | 1.00 | TSHR (0.55) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL19019770 | 1.00 | TSHR (0.55) | TSHRALDH1A1FASNFAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020048596-A1 | PREPARATION FOR THE TRANSPORT OF AN ACTIVE SUBSTANCE ACROSS BARRIERS | IDEA AG (DE) | 2002-04-25 | — | — | US | claimed |
| EP-4368657-A1 | PH-RESPONSIVE LIPID DERIVATIVE | NOF Corporation (JP) | 2024-05-15 | — | — | EP | disclosed |
| US-20240099976-A1 | BLENDED FORMULATIONS | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2024-03-28 | — | — | US | disclosed |
| US-20240009092-A1 | COSMETIC COMPOSITION AND COSMETIC QUASI-DRUG INCLUDING LIPID PARTICLES CONTAINING PHOSPHOLIPID | NIPPON SHOKUBAI CO., LTD. (JP) | 2024-01-11 | — | — | US | disclosed |
| WO-2023282296-A1 | PH-RESPONSIVE LIPID DERIVATIVE | 日油株式会社 | 2023-01-12 | — | — | WO | disclosed |
| US-11547665-B2 | Multiphasic compositions | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2023-01-10 | — | — | US | disclosed |
| EP-4021643-A1 | A COLLECTOR COMPOSITION FOR THE LITHIUM ORE OR MAGNESIUM ORE FLOTATION | BASF SE (DE) | 2022-07-06 | — | — | EP | disclosed |
| EP-3954361-A1 | MULTIPHASIC COMPOSITIONS | Sequessome Technology Holdings Limited (MT) | 2022-02-16 | — | — | EP | disclosed |
| US-20210393655-A1 | Vesicular Formulations for Use in the Treatment of Pain or Reduced Mobility of a Joint | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2021-12-23 | — | — | US | disclosed |
| EP-3316857-B1 | MULTIPHASIC COMPOSITIONS | SEQUESSOME TECH HOLDINGS LIMITED (MT) | 2021-08-04 | — | — | EP | disclosed |
| WO-2010090654-A1 | METHODS OF REDUCING THE PROLIFERATION AND VIABILITY OF MICROBIAL AGENTS | TDT, LTD. (MT) | 2010-08-12 | — | — | WO | disclosed |
| US-20100197621-A1 | METHODS OF REDUCING THE PROLIFERATION AND VIABILITY OF MICROBIAL AGENTS | TARGETED DELIVERY TECHNOLOGIES LIMITED (MT) | 2010-08-05 | — | — | US | disclosed |
| US-20100104633-A1 | antifungal formulations comprising terbinafine or a pharmaceutically acceptable salt thereof, a lipid, and a surfactant; uses thereof for the treatment of skin and nail fungal infections | CEVC GREGOR | 2010-04-29 | — | — | US | disclosed |
| US-20100086504-A1 | METHODS OF ADMINISTERING TOPICAL ANTIFUNGAL FORMULATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS | TDT LIMITED (MT) | 2010-04-08 | — | — | US | disclosed |
| WO-2010010470-A2 | METHODS OF ADMINISTERING TOPICAL ANTIFUNGAL FORMULATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS | TDT, LTD (MT) | 2010-01-28 | — | — | WO | disclosed |
| US-20020048596-A1 | PREPARATION FOR THE TRANSPORT OF AN ACTIVE SUBSTANCE ACROSS BARRIERS | IDEA AG (DE) | 2002-04-25 | — | — | US | disclosed |
| EP-0708645-A1 | USE OF COMPOUNDS WHICH INHIBIT PHOSPHATIDIC ACID FORMATION FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER | CELL THERAPEUTICS, INC. (US) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995024199-A2 | USE OF COMPOUNDS WHICH INHIBIT PHOSPHATIDIC ACID FORMATION FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER | CELL THERAPEUTICS, INC. (US) | 1995-09-14 | — | — | WO | disclosed |
| EP-0503508-A1 | Vesicles and polymeric vesicles | Kao Corporation (JP) | 1992-09-16 | — | — | EP | disclosed |
| EP-0036426-B1 | NOVEL PROCESS AND INTERMEDIATES USEFUL IN THE PREPARATION OF SYMPATHOMIMETIC AMINES | INTERx RESEARCH CORPORATION (US) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009092-A1 | COSMETIC COMPOSITION AND COSMETIC QUASI-DRUG INCLUDING LIPID PARTICLES CONTAINING PHOSPHOLIPID | PLIN5, PHOSPHO1, PLIN3 | TSHR 1575/4885ALDH1A1 524/4885FASN 174/4885 |
| US-20100104633-A1 | antifungal formulations comprising terbinafine or a pharmaceutically acceptable salt thereof, a lipid, and a surfactant; uses thereof for the treatment of skin and nail fungal infections | DPM1, PIK3C3, NACA | TSHR 3481/4885ALDH1A1 3968/4885FASN 689/4885 |
| US-20100086504-A1 | METHODS OF ADMINISTERING TOPICAL ANTIFUNGAL FORMULATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS | DPM1, ERG28, NACA | TSHR 3546/4885ALDH1A1 3533/4885FASN 289/4885 |
| US-20100197621-A1 | METHODS OF REDUCING THE PROLIFERATION AND VIABILITY OF MICROBIAL AGENTS | MGLL, LIPA, LPO | TSHR 4213/4885ALDH1A1 2166/4885FASN 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.